Abdel Hamad

Dr. Abdel Hamad


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Cytokine
Verified
Journal Article
Closed access
ASAnkit Saxena
Ankit Saxena
SKSam Khosraviani
Sam Khosraviani
SNSanjeev Noel
Sanjeev Noel
DMDivya Mohan
Divya Mohan
TDThomas Donner
Thomas Donner
AHAbdel Hamad
Abdel Hamad

1 May 2019 in Cell
Verified
Journal Article
Closed access
RARizwan Ahmed
Rizwan Ahmed
ZOZahra Omidian
Zahra Omidian
AGAdebola Giwa
Adebola Giwa
BCBenjamin Cornwell
Benjamin Cornwell
NMNeha Majety
Neha Majety
AHAbdel Hamad
Abdel Hamad

15 January 2020 in World Journal of Diabetes
Verified
Journal Article
Open access
AGAdebola Matthew Giwa
Adebola Matthew Giwa
RARizwan Ahmed
Rizwan Ahmed
ZOZahra Omidian
Zahra Omidian
NMNeha Majety
Neha Majety
KKKagan Ege Karakus
Kagan Ege Karakus
AHAbdel Hamad
Abdel Hamad
Type 1 diabetes (T1D) is an autoimmune disease that usually strikes early in life, but can affect individuals at almost any age. It is caused by autoreactive T cells that destroy insulin-producing beta cells in the pancreas. Epidemiological studies estimate a prevalence of 1 in 300 children in the United States with an increasing incidence of 2%-5% annually worldwide. The daily responsibility, clinical management, and vigilance required to maintain blood sugar levels within normal range and avoid acute complications (hypoglycemic episodes and diabetic ketoacidosis) and long term micro- and macro-vascular complications significantly affects quality of life and public health care costs. Given the expansive impact of T1D, research work has accelerated and T1D has been intensively investigated with the focus to better understand, manage and cure this condition. Many advances have been made in the past decades in this regard, but key questions remain as to why certain people develop T1D, but not others, with the glaring example of discordant disease incidence among monozygotic twins. In this review, we discuss the field's current understanding of its pathophysiology and the role of genetics and environment on the development of T1D. We examine the potential implications of these findings with an emphasis on T1D inheritance patterns, twin studies, and disease prevention. Through a better understanding of this process, interventions can be developed to prevent or halt it at early stages.

25 November 2014 in Immunology & Cell Biology
Verified
Journal Article
Open access
PDF file
MMMaria N Martina
Maria N Martina
SNSanjeev Noel
Sanjeev Noel
ASAnkit Saxena
Ankit Saxena
HRHamid Rabb
Hamid Rabb
AHAbdel Hamad
Abdel Hamad
CD4−CD8−double negative (DN) αβ T cells are legitimate components of the normal immune system. However, they are poorly understood and largely ignored by immunologists because of their historical association with the lymphoproliferation that occurs in mice (lpr and gld) and humans (autoimmune lymphoproliferative syndromes patients) with impaired Fas‐mediated apoptosis where they are considered abnormal T cells. We believe that the traditional view that DN T cells that cause lymphoproliferation (hereafter referred to as lpr DN T cells) are CD4 and CD8 T cells that lost their coreceptor, conceived more than two decades ago, is flawed and that conflating lpr DN T cells with DN T cells found in normal immune system (hereafter referred to as nDN T cells) is unnecessarily dampening interest of this potentially important cell type. To begin rectifying these misperceptions, we will revisit the traditional view of lpr DN T cells and show that it does not hold true in light of recent immunological advances. In lieu of it, we offer a new model proposing that Fas‐mediated apoptosis actively removes normally existing DN T cells from the periphery and that impaired Fas‐mediated apoptosis leads to accumulation of these cells rather than de novo generation of DN T cells from activated CD4 or CD8 T cells. By doing so, we hope to provoke a new discussion that may lead to a consensus about the origin of lpr DN T cells and regulation of their homeostasis by the Fas pathway and reignite wider interest in nDN T cells.

1 September 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
AHAbdel Hamad
Abdel Hamad
AMAbdiaziz S Mohamood
Abdiaziz S Mohamood
CTCrystal J Trujillo
Crystal J Trujillo
CHChing-Tai Huang
Ching-Tai Huang
EYEmily Yuan
Emily Yuan
JSJonathan P Schneck
Jonathan P Schneck
Fas-mediated apoptosis is a key mechanism for elimination of autoreactive T cells, yet loss of function mutations in the Fas signaling pathway does not result in overt T cell-mediated autoimmunity. Furthermore, mice and humans with homozygous Faslpr or Fas ligandgld mutations develop significant numbers of B220+ CD4− CD8− double-negative (DN) αβ T cells (hereafter referred to as B220+ DN T cells) of poorly understood function. In this study, we show that B220+ DN T cells, whether generated in vitro or isolated from mutant mice, can suppress the ability of activated T cells to proliferate or produce IL-2, IL-10, and IFN-γ. B220+ DN T cells that were isolated from either lpr or gld mice were able to suppress proliferation of autologous and syngeneic CD4 T cells, showing that suppression is Fas independent. Furthermore, restoration of Fas/Fas ligand interaction did not enhance suppression. The mechanism of suppression involves inhibition of IL-2 production and its high affinity IL-2R α-chain (CD25). Suppression also requires cell/cell contact and TCR activation of B220+ DN T cells, but not soluble cytokines. These findings suggest that B220+ DN T cells may be involved in controlling autoreactive T cells in the absence of Fas-mediated peripheral tolerance.

21 October 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAbdiaziz S Mohamood
Abdiaziz S Mohamood
DBDylan Bargatze
Dylan Bargatze
ZXZuoxiang Xiao
Zuoxiang Xiao
CJChunfa Jie
Chunfa Jie
HYHideo Yagita
Hideo Yagita
AHAbdel Hamad
Abdel Hamad
The Fas pathway is a major regulator of T cell homeostasis, however, the T cell population that is controlled by the Fas pathway in vivo is poorly defined. Although CD4 and CD8 single positive (SP) T cells are the two major T cell subsets in the periphery of wild type mice, the repertoire of mice bearing loss-of-function mutation in either Fas (lpr mice) or Fas ligand (gld mice) is predominated by CD4−CD8− double negative αβ T cells that also express B220 and generally referred to as B220+DN T cells. Despite extensive analysis, the basis of B220+DN T cell lymphoproliferation remains poorly understood. In this study we re-examined the issue of why T cell lymphoproliferation caused by gld mutation is predominated by B220+DN T cells. We combined the following approaches to study this question: Gene transcript profiling, BrdU labeling, and apoptosis assays. Our results show that B220+DN T cells are proliferating and dying at exceptionally high rates than SP T cells in the steady state. The high proliferation rate is restricted to B220+DN T cells found in the gut epithelium whereas the high apoptosis rate occurred both in the gut epithelium and periphery. However, only in the periphery, apoptosis of B220+DN T cell is Fas-dependent. When the Fas pathway is genetically impaired, apoptosis of peripheral B220+DN T cells was reduced to a baseline level similar to that of SP T cells. Under these conditions of normalized apoptosis, B220+DN T cells progressively accumulate in the periphery, eventually resulting in B220+DN T cell lymphoproliferation. The Fas pathway plays a critical role in regulating the tissue distribution of DN T cells through targeting and elimination of DN T cells from the periphery in the steady state. The results provide new insight into pathogenesis of DN T cell lymphoproliferation.